Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

In this article

Novo Nordisk

on Monday said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price, as drugmakers face mounting political pressure to lower prices in the country.

Patients can pay $499 in cash per month for three dose sizes of Ozempic. They can get the price through platforms including the drug’s official website, Novo Nordisk’s patient assistance program and the company’s recently launched direct-to-consumer online pharmacy, the latter of which also ships the injection directly to patients’ homes.

Drug savings company GoodRx will also offer Ozempic and its weight loss counterpart Wegovy for $499 per month, making the discounts available at more than 70,000 pharmacies nationwide, according to a Novo Nordisk release.